{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:56:51Z","timestamp":1790035011457,"version":"4.0.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:00:00Z","timestamp":1709424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.gore.2024.101359","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T11:51:06Z","timestamp":1709639466000},"page":"101359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Clinical outcomes following identification of an incidental p53 signature in the fallopian tube"],"prefix":"10.1016","volume":"52","author":[{"given":"Emily C.","family":"MacARTHUR","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzy","family":"RADOLEC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Rinda SOONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"ELISHAEV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"BUCKANOVICH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"TAYLOR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"LESNOCK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gore.2024.101359_b0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J Natl Compr Canc Netw."},{"issue":"2","key":"10.1016\/j.gore.2024.101359_b0010","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ygyno.2008.01.012","article-title":"A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations","volume":"109","author":"Folkins","year":"2008","journal-title":"Gynecol Oncol."},{"issue":"1","key":"10.1016\/j.gore.2024.101359_b0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13000-018-0702-3","article-title":"High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis","volume":"13","author":"Hatano","year":"2018","journal-title":"Diagn Pathol."},{"issue":"1","key":"10.1016\/j.gore.2024.101359_b0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J Pathol."},{"issue":"3","key":"10.1016\/j.gore.2024.101359_b0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/PAT.0b013e32835f2264","article-title":"Precursors and pathogenesis of ovarian carcinoma","volume":"45","author":"Lim","year":"2013","journal-title":"Pathology"},{"issue":"2","key":"10.1016\/j.gore.2024.101359_b0030","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for Early Adenocarcinoma in women with familial Ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"issue":"21","key":"10.1016\/j.gore.2024.101359_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215482","article-title":"The association and significance of p53 in gynecologic cancers: the potential of targeted therapy","volume":"20","author":"Nakamura","year":"2019","journal-title":"Int J Mol Sci."},{"issue":"22","key":"10.1016\/j.gore.2024.101359_b0040","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1002\/cncr.25439","article-title":"The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations","volume":"116","author":"Norquist","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.gore.2024.101359_b0045","unstructured":"Ovarian Cancer \u2014 Cancer Stat Facts. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html. Accessed January 25, 2022."},{"issue":"2","key":"10.1016\/j.gore.2024.101359_b0050","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2008.07.018","article-title":"Risk factors for a serous cancer precursor (\u201cp53 signature\u201d) in women with inherited BRCA mutations","volume":"111","author":"Saleemuddin","year":"2008","journal-title":"Gynecol Oncol."},{"issue":"3","key":"10.1016\/j.gore.2024.101359_b0055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/path.5145","article-title":"Evidence for lineage continuity between early serous proliferations (ESPs) in the fallopian tube and disseminated high-grade serous carcinomas","volume":"246","author":"Soong","year":"2018","journal-title":"J Pathol."},{"issue":"2","key":"10.1016\/j.gore.2024.101359_b0060","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ygyno.2018.11.033","article-title":"The fallopian tube, \u201cprecursor escape\u201d and narrowing the knowledge gap to the origins of high-grade serous carcinoma","volume":"152","author":"Soong","year":"2019","journal-title":"Gynecol Oncol."},{"issue":"2","key":"10.1016\/j.gore.2024.101359_b0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ygyno.2020.04.707","article-title":"Fallopian tube abnormalities in uterine serous carcinoma","volume":"158","author":"Steenbeek","year":"2020","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.gore.2024.101359_b0070","unstructured":"The Role of the Fallopian Tube in Ovarian Cancer \u2013 Hematology & Oncology. https:\/\/www.hematologyandoncology.net\/archives\/may-2012\/the-role-of-the-fallopian-tube-in-ovarian-cancer\/. Accessed March 1, 2022."},{"issue":"1","key":"10.1016\/j.gore.2024.101359_b0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41379-019-0370-1","article-title":"Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions","volume":"33","author":"Wu","year":"2020","journal-title":"Mod Pathol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578924000389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578924000389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:59:34Z","timestamp":1762480774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578924000389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":15,"alternative-id":["S2352578924000389"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2024.101359","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes following identification of an incidental p53 signature in the fallopian tube","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2024.101359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101359"}}